SWOG clinical trial number
SWOG-9140
Phase II Study of Oral Bropirimine Combined with Intravesical Bacillus Calmette - Guerin (Tice) in Patients with Carcinoma in Situ of the Bladder
Closed
Phase
Accrual
100%
Published
Abbreviated Title
Bladder
Activated
12/01/1992
Closed
12/01/1997
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
2005
A phase II clinical trial of oral bropirimine in combination with intravesical bacillus calmette-guerin for carcinoma in situ of the bladder: a Southwest Oncology Group study
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase